Entrada Therapeutics, Inc. (TRDA) Profit Margin
Entrada Therapeutics, Inc. (TRDA) net profit margin by fiscal period. Analyze profit margins in Excel with MarketXLS.
Profit Margin Data
| Period | Net Profit Margin |
|---|---|
| 2021-12-31 | N/A |
| 2022-12-31 | N/A |
| 2023-12-31 | -5.18% |
| 2024-12-31 | 31.13% |
| 2025-12-31 | -565.48% |
How TRDA compares with sector peers
| Symbol | Company | Net profit margin (latest fiscal year) |
|---|---|---|
| KURA | Kura Oncology Inc. | -412.95% |
| OCUL | Ocular Therapeutix Inc. | -511.90% |
| NTLA | Intellia Therapeutics Inc. | -609.85% |
| ALEC | Alector Inc. | -679.16% |
| HSDT | Helius Medical Technologies Inc. | -679.57% |
These are five companies in the same sector as TRDA with a comparable annual net profit margin. Each figure above is that company's most recent completed fiscal year, read from the same annual statements as the table on its own page, so the period end dates can differ between rows.
Get Entrada Therapeutics, Inc. Data in Excel
Stream real-time stock prices and financials directly into your spreadsheets with MarketXLS.
Try: =hf_Profit_Margin("TRDA", 2024)
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Volume |
| 2 | TRDA | $7.46 | +0.00% | 0.24M |
| 3 | ||||
| 4 | ||||
| 5 |